PEG-Loxenatide Meta-Analysis: 5.5 kg Weight Loss in Obese Diabetics and Better Blood Sugar Control
A meta-analysis of 1,248 patients found that PEG-loxenatide (a long-acting GLP-1 agonist) significantly improved blood sugar control and produced 5.46 kg weight loss in obese diabetics when combined with metformin.
Quick Facts
What This Study Found
PEG-loxenatide (PEX168), a long-acting pegylated GLP-1 receptor agonist derived from exenatide, significantly improved blood sugar control when added to metformin. The meta-analysis of 6 RCTs with 1,248 patients found that PEX168 plus metformin significantly reduced fasting blood glucose (MD = -1.20 mmol/L) and HbA1c compared to metformin alone.
Weight loss was striking in obese patients — a 5.46 kg reduction versus controls — but no weight change occurred in non-obese patients. PEX168 monotherapy at 100, 200, and 300 μg showed comparable diabetes control to metformin. The 100 μg dose combined with metformin offered the best balance of efficacy and safety, while the 200 μg combination had more nausea and vomiting.
Key Numbers
6 RCTs · n=1,248 · FBG: MD = -1.20 mmol/L (p<0.001) · Weight loss in obese: -5.46 kg (p<0.0001) · Weight in non-obese: no change (p=0.83) · Doses: 100, 200, 300 μg · GI side effects more common (p<0.05)
How They Did This
Systematic review and meta-analysis of randomized controlled trials. The authors searched PubMed, Scopus, Cochrane Library, and Web of Science through April 2023. Six RCTs with 1,248 participants were included. Outcomes were analyzed using mean differences for continuous data and risk ratios for binary outcomes with 95% confidence intervals. Subgroup analyses examined different doses and obese versus non-obese patients.
Why This Research Matters
PEG-loxenatide is a Chinese-developed GLP-1 agonist that offers once-weekly dosing through pegylation of exenatide. This meta-analysis provides the most comprehensive evidence synthesis to date, showing it's a viable option for patients who don't achieve adequate control with metformin alone. The selective weight loss in obese but not non-obese patients is an interesting pharmacological distinction from other GLP-1 drugs.
The Bigger Picture
The GLP-1 agonist market is dominated by Western-developed drugs like semaglutide and tirzepatide. PEG-loxenatide represents China's growing contribution to this therapeutic class. While it may not match the weight loss efficacy of newer agents, it provides an important option in the Chinese market and demonstrates that pegylation is a viable strategy for extending peptide drug half-lives.
What This Study Doesn't Tell Us
Only 6 trials were available, limiting statistical power for subgroup analyses. All trials were likely conducted in Chinese populations, which may limit generalizability to other ethnic groups. The trials varied in design (monotherapy vs. combination). Long-term safety and cardiovascular outcomes data were not available. The authors note findings should be interpreted with caution due to the small number of trials.
Questions This Raises
- ?How does PEG-loxenatide's weight loss efficacy compare head-to-head with semaglutide or tirzepatide?
- ?Why does PEG-loxenatide produce weight loss in obese but not non-obese diabetics — does this reflect a threshold effect?
- ?Will PEG-loxenatide be studied for cardiovascular outcomes like the major Western GLP-1 agonist trials?
Trust & Context
- Key Stat:
- -5.46 kg Weight loss in obese diabetic patients receiving PEG-loxenatide versus controls, with no weight change in non-obese patients
- Evidence Grade:
- This is a systematic review and meta-analysis of 6 randomized controlled trials — one of the strongest study designs. However, the relatively small number of trials and the likely homogeneous study population (Chinese patients) limit generalizability.
- Study Age:
- Published in 2023, this meta-analysis represents the most current synthesis of PEG-loxenatide clinical evidence. The drug is relatively new compared to established GLP-1 agonists.
- Original Title:
- Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
- Published In:
- Scientific reports, 13(1), 19041 (2023)
- Authors:
- Salamah, Hazem Mohamed(2), Marey, Ahmed(3), Elsayed, Esraa, Hasan, Mohammed Tarek, Mahmoud, Abdelrahman, Abualkhair, Khaled Alsayed, Abo-Elnour, Dina Essam, Abdelhaleem, Ibrahim Abdelmonaem, Abd-Elgawad, Mohamed
- Database ID:
- RPEP-07340
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How is PEG-loxenatide different from other GLP-1 drugs?
PEG-loxenatide is a pegylated version of exenatide — a PEG molecule is attached to extend its half-life, allowing once-weekly dosing. It's developed in China and primarily available there, unlike semaglutide (Novo Nordisk, Denmark) or tirzepatide (Eli Lilly, USA).
Why did non-obese patients not lose weight?
The meta-analysis found that PEG-loxenatide produced 5.46 kg weight loss in obese patients but essentially no change in non-obese patients. This may reflect that GLP-1 appetite suppression has a greater impact when there's excess adipose tissue to lose, though the exact mechanism for this difference is not explained in the study.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-07340APA
Salamah, Hazem Mohamed; Marey, Ahmed; Elsayed, Esraa; Hasan, Mohammed Tarek; Mahmoud, Abdelrahman; Abualkhair, Khaled Alsayed; Abo-Elnour, Dina Essam; Abdelhaleem, Ibrahim Abdelmonaem; Abd-Elgawad, Mohamed. (2023). Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.. Scientific reports, 13(1), 19041. https://doi.org/10.1038/s41598-023-46274-x
MLA
Salamah, Hazem Mohamed, et al. "Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.." Scientific reports, 2023. https://doi.org/10.1038/s41598-023-46274-x
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of polyethylene glycol loxenatide in typ..." RPEP-07340. Retrieved from https://rethinkpeptides.com/research/salamah-2023-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.